ETFs Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:10 2025-06-24 EDT			5-day change	1st Jan Change
1,025.00 ^GBX	+1.59%		-0.39%	+0.10%

06-19	Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users	CI
06-05	UK Market Exodus: Companies that have moved away from a London listing	RE

ETFs positioned on Indivior PLC

Name	Weight	AuM	1st Jan change
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0%	59 M€	+3.82%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	-0%	27 M€	0.00%	-

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

06-24 - Northland Growth Conference

More about the company